MX347164B - Anticuerpos anti-il-36r. - Google Patents
Anticuerpos anti-il-36r.Info
- Publication number
- MX347164B MX347164B MX2014005759A MX2014005759A MX347164B MX 347164 B MX347164 B MX 347164B MX 2014005759 A MX2014005759 A MX 2014005759A MX 2014005759 A MX2014005759 A MX 2014005759A MX 347164 B MX347164 B MX 347164B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- therapeutic
- compositions
- same
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos anti-IL-36R y composiciones farmacéuticas que los contienen.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161560554P | 2011-11-16 | 2011-11-16 | |
| US201261644111P | 2012-05-08 | 2012-05-08 | |
| US201261713713P | 2012-10-15 | 2012-10-15 | |
| PCT/US2012/064933 WO2013074569A1 (en) | 2011-11-16 | 2012-11-14 | Anti il-36r antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005759A MX2014005759A (es) | 2014-09-08 |
| MX347164B true MX347164B (es) | 2017-04-18 |
Family
ID=47215803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005759A MX347164B (es) | 2011-11-16 | 2012-11-14 | Anticuerpos anti-il-36r. |
Country Status (41)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| FI3536710T3 (fi) | 2011-11-16 | 2026-01-14 | Boehringer Ingelheim Int | Anti-il-36r -vasta-aineita |
| EP3093294A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
| TWI777174B (zh) * | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| RU2582569C2 (ru) * | 2014-07-24 | 2016-04-27 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом |
| CN107847589B (zh) | 2015-04-01 | 2022-03-29 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体 |
| PL3283110T3 (pl) * | 2015-04-15 | 2022-06-27 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) |
| WO2016201282A2 (en) * | 2015-06-12 | 2016-12-15 | Ludwig Institute For Cancer Research Ltd | TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| JP6654773B2 (ja) * | 2015-12-25 | 2020-02-26 | 国立大学法人名古屋大学 | インターロイキン３６受容体アンタゴニスト欠損症の治療薬 |
| BR112019008861A2 (pt) | 2016-11-01 | 2019-07-09 | Tesaro, Inc. | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| SG10201913083SA (en) | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
| JP2020512344A (ja) * | 2017-03-27 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−３６ｒ抗体併用治療 |
| MA50424A (fr) * | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 |
| WO2019177883A2 (en) * | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| WO2019177888A1 (en) * | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
| WO2020018503A2 (en) * | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Anti-il36r antibodies |
| HRP20240999T1 (hr) | 2018-07-16 | 2024-10-25 | Regeneron Pharmaceuticals, Inc. | Glodavački modeli bolesti ditra i njihova upotreba |
| CN112638946A (zh) | 2018-08-16 | 2021-04-09 | 坎塔吉亚有限责任公司 | 抗il1rap抗体组合物 |
| TW202019958A (zh) * | 2018-09-28 | 2020-06-01 | 日商協和麒麟股份有限公司 | Il-36抗體及其用途 |
| EP3898673A1 (en) * | 2018-12-21 | 2021-10-27 | 23Andme, Inc. | Anti-il-36 antibodies and methods of use thereof |
| AU2019416727A1 (en) * | 2018-12-27 | 2021-07-22 | Boehringer Ingelheim International Gmbh | Anti-il-36R antibodies for treatment of palmoplantar pustulosis |
| KR20210137520A (ko) * | 2019-03-08 | 2021-11-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-36r 항체 제형 |
| JP7811772B2 (ja) * | 2019-12-05 | 2026-02-06 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
| AR120913A1 (es) * | 2019-12-27 | 2022-03-30 | Teijin Pharma Ltd | Anticuerpo que inhibe específicamente la señalización de il-36r |
| EP4153233A1 (en) | 2020-05-19 | 2023-03-29 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for the treatment of atopic dermatitis |
| JP7812364B2 (ja) | 2020-07-17 | 2026-02-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体 |
| WO2022026832A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis |
| WO2022026829A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| CA3192882A1 (en) | 2020-09-30 | 2022-04-07 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for treatment of chronic inflammatory pain |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| WO2022127842A1 (zh) * | 2020-12-17 | 2022-06-23 | 上海华奥泰生物药业股份有限公司 | 靶向il-17a和il-36r的双特异性抗体及其应用 |
| WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
| WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
| WO2022166977A1 (zh) * | 2021-02-08 | 2022-08-11 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| EP4301409A1 (en) | 2021-03-04 | 2024-01-10 | Boehringer Ingelheim International GmbH | Methods for the treatment of gpp |
| WO2022192531A2 (en) | 2021-03-12 | 2022-09-15 | Boehringer Ingelheim International Gmbh | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| BR112023017717A2 (pt) * | 2021-05-03 | 2024-01-09 | Boehringer Ingelheim Int | Método para produção de espesolimabe |
| EP4357361A4 (en) * | 2021-06-18 | 2025-09-03 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | ANTI-IL-36R ANTIBODY AND ITS USE |
| EP4370550A1 (en) | 2021-07-12 | 2024-05-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
| US20230049147A1 (en) | 2021-08-13 | 2023-02-16 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for the treatment of a fibrotic condition |
| EP4409592A2 (en) | 2021-09-28 | 2024-08-07 | Boehringer Ingelheim International Gmbh | System and method for assessing severity of neutrophilic dermatoses with visible skin manifestation |
| TW202334200A (zh) | 2021-10-28 | 2023-09-01 | 美商艾伯維有限公司 | 抗澱粉樣蛋白β抗體及其使用方法 |
| TW202323293A (zh) * | 2021-10-29 | 2023-06-16 | 新加坡商創響私人有限公司 | 新型抗ｉｌ－３６ｒ抗體 |
| CN115724975A (zh) * | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
| CN116574189A (zh) | 2023-01-30 | 2023-08-11 | 北京智仁美博生物科技有限公司 | 针对人il-36r和/或人il-1r3的多种抗体及其用途 |
| WO2024175031A1 (zh) | 2023-02-21 | 2024-08-29 | 江苏恒瑞医药股份有限公司 | Il-36r结合蛋白及其医药用途 |
| JP2026507877A (ja) | 2023-03-09 | 2026-03-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 化膿性汗腺炎（ｈｓ）を処置するための抗ｉｌ－３６ｒ抗体の使用 |
| KR20260025132A (ko) | 2023-06-09 | 2026-02-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 전신 농포성 건선(gpp)의 치료 및 예방 방법 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| DK0656789T3 (da) | 1992-08-21 | 1998-08-24 | Genentech Inc | Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse. |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| ATE523593T1 (de) | 1997-08-01 | 2011-09-15 | Schering Corp | Membranproteine aus säugetierzellen und verwandte reagentien |
| ES2637801T3 (es) * | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| EP1627927A3 (en) * | 2001-03-01 | 2006-06-07 | Epigenomics AG | Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA |
| WO2004031362A2 (en) * | 2002-10-03 | 2004-04-15 | Large Scale Biology Corporation | Multimeric protein engineering |
| EP2500352A1 (en) * | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US8034771B2 (en) * | 2006-09-08 | 2011-10-11 | Amgen Inc. | IL-1F6 polypeptides |
| MX2009011500A (es) | 2007-04-23 | 2010-01-29 | Schering Corp | Anticuerpos anti-mdl-1. |
| AU2008270710A1 (en) | 2007-06-29 | 2009-01-08 | Merck Sharp & Dohme Corp. | MDL-1 uses |
| RU2011105466A (ru) * | 2008-08-28 | 2012-10-10 | ВАЙЕТ ЭлЭлСи (US) | Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях |
| FI3536710T3 (fi) | 2011-11-16 | 2026-01-14 | Boehringer Ingelheim Int | Anti-il-36r -vasta-aineita |
| PL3283110T3 (pl) | 2015-04-15 | 2022-06-27 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) |
-
2012
- 2012-11-14 FI FIEP19169065.0T patent/FI3536710T3/fi active
- 2012-11-14 KR KR1020197030980A patent/KR102159109B1/ko active Active
- 2012-11-14 EP EP19169065.0A patent/EP3536710B1/en active Active
- 2012-11-14 WO PCT/US2012/064933 patent/WO2013074569A1/en not_active Ceased
- 2012-11-14 HR HRP20251675TT patent/HRP20251675T1/hr unknown
- 2012-11-14 SI SI201231692T patent/SI2780373T1/sl unknown
- 2012-11-14 EA EA201400579A patent/EA031948B1/ru not_active IP Right Cessation
- 2012-11-14 JP JP2014542388A patent/JP6289375B2/ja active Active
- 2012-11-14 CN CN202011390234.3A patent/CN112812183B/zh active Active
- 2012-11-14 CN CN201610916419.0A patent/CN107007833B/zh active Active
- 2012-11-14 CN CN202410673234.6A patent/CN118515766A/zh active Pending
- 2012-11-14 SG SG11201402283PA patent/SG11201402283PA/en unknown
- 2012-11-14 DK DK12788410T patent/DK2780373T3/da active
- 2012-11-14 US US13/676,511 patent/US9023995B2/en active Active
- 2012-11-14 RS RSP20191179 patent/RS59248B1/sr unknown
- 2012-11-14 AP AP2014007571A patent/AP2014007571A0/xx unknown
- 2012-11-14 PL PL12788410T patent/PL2780373T3/pl unknown
- 2012-11-14 AU AU2012339734A patent/AU2012339734B2/en active Active
- 2012-11-14 ES ES12788410T patent/ES2755732T3/es active Active
- 2012-11-14 MX MX2014005759A patent/MX347164B/es active IP Right Grant
- 2012-11-14 EP EP12788410.4A patent/EP2780373B1/en active Active
- 2012-11-14 PT PT191690650T patent/PT3536710T/pt unknown
- 2012-11-14 UA UAA201406586A patent/UA115540C2/uk unknown
- 2012-11-14 CN CN202410673612.0A patent/CN118496365A/zh active Pending
- 2012-11-14 ES ES19169065T patent/ES3058874T3/es active Active
- 2012-11-14 PE PE2014000705A patent/PE20142041A1/es active IP Right Grant
- 2012-11-14 KR KR1020147013267A patent/KR102038310B1/ko active Active
- 2012-11-14 LT LTEP12788410.4T patent/LT2780373T/lt unknown
- 2012-11-14 BR BR112014011594-0A patent/BR112014011594B1/pt active IP Right Grant
- 2012-11-14 HR HRP20191835TT patent/HRP20191835T1/hr unknown
- 2012-11-14 DK DK19169065.0T patent/DK3536710T3/da active
- 2012-11-14 LT LTEP19169065.0T patent/LT3536710T/lt unknown
- 2012-11-14 CN CN201280054425.XA patent/CN104080808B/zh active Active
- 2012-11-14 GE GEAP201713499A patent/GEP20186816B/en unknown
- 2012-11-14 HU HUE12788410A patent/HUE047437T2/hu unknown
- 2012-11-14 KR KR1020207026736A patent/KR20200110476A/ko not_active Ceased
- 2012-11-14 PT PT127884104T patent/PT2780373T/pt unknown
- 2012-11-14 RS RS20260044A patent/RS67639B1/sr unknown
- 2012-11-14 MY MYPI2019000058A patent/MY195289A/en unknown
- 2012-11-14 CA CA2852994A patent/CA2852994C/en active Active
- 2012-11-15 TW TW101142698A patent/TWI573804B/zh active
- 2012-11-15 AR ARP120104313A patent/AR089178A1/es active IP Right Grant
- 2012-11-16 UY UY0001034456A patent/UY34456A/es active IP Right Grant
-
2014
- 2014-04-04 ZA ZA2014/02491A patent/ZA201402491B/en unknown
- 2014-04-13 IL IL232100A patent/IL232100B/en active IP Right Grant
- 2014-04-29 CL CL2014001123A patent/CL2014001123A1/es unknown
- 2014-05-14 CO CO14103887A patent/CO7020871A2/es unknown
- 2014-05-16 PH PH12014501108A patent/PH12014501108B1/en unknown
- 2014-06-13 EC ECIEPI20144976A patent/ECSP14004976A/es unknown
-
2015
- 2015-04-01 US US14/676,365 patent/US10550189B2/en active Active
-
2018
- 2018-02-06 JP JP2018019080A patent/JP6719490B2/ja active Active
-
2019
- 2019-11-12 CY CY20191101185T patent/CY1122278T1/el unknown
- 2019-12-17 US US16/717,413 patent/US20200231684A1/en not_active Abandoned
-
2020
- 2020-01-14 IL IL272035A patent/IL272035A/en unknown
- 2020-06-16 JP JP2020103873A patent/JP2020156506A/ja active Pending
-
2023
- 2023-05-23 CY CY2023014C patent/CY2023014I2/el unknown
- 2023-05-26 LT LTPA2023518C patent/LTC2780373I2/lt unknown
- 2023-05-30 NO NO2023024C patent/NO2023024I1/no unknown
- 2023-05-31 NL NL301233C patent/NL301233I2/nl unknown
- 2023-05-31 FR FR23C1023C patent/FR23C1023I2/fr active Active
- 2023-05-31 LU LU00308C patent/LUC00308I2/fr unknown
- 2023-06-01 FI FIC20230020C patent/FIC20230020I1/fi unknown
- 2023-06-05 HU HUS2300021C patent/HUS2300021I1/hu unknown
-
2024
- 2024-08-27 US US18/815,907 patent/US20240409648A1/en active Pending
-
2025
- 2025-01-03 NO NO2025001C patent/NO2025001I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347164B (es) | Anticuerpos anti-il-36r. | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| TN2012000462A1 (en) | Anti-cd40 antibodies | |
| PT2766380T (pt) | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos | |
| TN2014000134A1 (en) | Therapeutic peptides | |
| PH12015501263A1 (en) | Compositions comprising anti-cd38 antibodies and lenalidomide | |
| IN2014DN08481A (es) | ||
| MX2013006875A (es) | Anticuepos anti-notch1. | |
| MX2014002996A (es) | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. | |
| WO2012109238A3 (en) | Methods for increasing immune responses using agents that directly bind to and activate ire-1 | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| MX2018008882A (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| WO2013093627A3 (en) | In silico affinity maturation | |
| TN2014000207A1 (en) | Anti il-36r antibodies | |
| AR123070A2 (es) | Anticuerpos anti-il-23 | |
| TN2013000186A1 (en) | Anti-il-23 antibodies | |
| TN2013000265A1 (en) | Anti-cd38 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |